HC Wainwright reiterated their buy rating on shares of Rubius Therapeutics (NASDAQ:RUBY) in a report issued on Friday morning, Stock Target Advisor reports. HC Wainwright currently has a $40.00 price target on the stock.

RUBY has been the topic of a number of other research reports. Zacks Investment Research lowered shares of Rubius Therapeutics from a buy rating to a sell rating in a research report on Wednesday, November 13th. ValuEngine raised shares of Rubius Therapeutics from a hold rating to a buy rating in a research report on Thursday, August 1st. JPMorgan Chase & Co. dropped their price target on shares of Rubius Therapeutics from $27.00 to $22.00 and set an overweight rating on the stock in a research report on Thursday, August 29th. Finally, Robert W. Baird started coverage on shares of Rubius Therapeutics in a research report on Monday, September 9th. They issued an underperform rating and a $4.00 price target on the stock. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $18.67.

Shares of NASDAQ:RUBY traded up $0.24 during trading on Friday, reaching $7.60. The stock had a trading volume of 366,400 shares, compared to its average volume of 280,120. Rubius Therapeutics has a 52 week low of $6.96 and a 52 week high of $23.98. The firm has a market capitalization of $627.65 million, a price-to-earnings ratio of -3.24 and a beta of 2.26. The company has a quick ratio of 17.27, a current ratio of 17.27 and a debt-to-equity ratio of 0.21. The stock has a fifty day simple moving average of $9.00 and a two-hundred day simple moving average of $12.26.

Rubius Therapeutics (NASDAQ:RUBY) last released its quarterly earnings results on Thursday, November 14th. The company reported ($0.59) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.06). During the same quarter in the prior year, the company earned ($0.42) EPS. On average, analysts forecast that Rubius Therapeutics will post -2.02 EPS for the current year.

In other news, insider Christopher L. Carpenter sold 48,000 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $10.11, for a total value of $485,280.00. Also, Director Robert Langer sold 7,500 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $9.25, for a total transaction of $69,375.00. Company insiders own 58.40% of the company’s stock.

Several institutional investors have recently made changes to their positions in RUBY. Metropolitan Life Insurance Co NY boosted its stake in Rubius Therapeutics by 65.0% during the first quarter. Metropolitan Life Insurance Co NY now owns 11,867 shares of the company’s stock worth $214,000 after buying an additional 4,676 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Rubius Therapeutics by 147.3% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,241,299 shares of the company’s stock worth $19,526,000 after buying an additional 739,449 shares in the last quarter. Nikko Asset Management Americas Inc. boosted its stake in Rubius Therapeutics by 142.3% during the second quarter. Nikko Asset Management Americas Inc. now owns 1,254,158 shares of the company’s stock worth $19,728,000 after buying an additional 736,490 shares in the last quarter. ARK Investment Management LLC boosted its stake in Rubius Therapeutics by 31.9% during the second quarter. ARK Investment Management LLC now owns 698,402 shares of the company’s stock worth $10,986,000 after buying an additional 168,787 shares in the last quarter. Finally, Swiss National Bank acquired a new stake in Rubius Therapeutics during the second quarter worth $934,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Rubius Therapeutics

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.

Recommended Story: Inverted Yield Curve

Analyst Recommendations for Rubius Therapeutics (NASDAQ:RUBY)

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.